Understanding the changing prevalence of K65R

Selection of the reverse transcriptase mutation K65R has been a matter of concern because the mutation may result in broad cross-resistance, reducing susceptibility to all other approved nucleoside reverse transcriptase inhibitors (NRTI), except zidovudine. The mutation is selected mainly by tenofov...

Full description

Saved in:
Bibliographic Details
Published inAIDS reviews Vol. 10; no. 2; p. 125
Main Authors Theys, Kristof, Vandamme, Anne-Mieke
Format Journal Article
LanguageEnglish
Published Spain 01.04.2008
Subjects
Drug Resistance, Viral
HIV - drug effects
HIV - genetics
HIV - isolation & purification
HIV Infections - virology
HIV Reverse Transcriptase - genetics
Humans
Mutation, Missense
Reverse Transcriptase Inhibitors - pharmacology
Online AccessGet full text

Cover

More Information
Summary:Selection of the reverse transcriptase mutation K65R has been a matter of concern because the mutation may result in broad cross-resistance, reducing susceptibility to all other approved nucleoside reverse transcriptase inhibitors (NRTI), except zidovudine. The mutation is selected mainly by tenofovir (TDF) and to a lesser extent by didanosine (ddI) and abacavir (ABC). Despite the wide use of K65R-selecting drugs, the overall prevalence in treatment-experienced patients has been quite low. However, an increasing trend in prevalence and incidence has been observed in recent years, which is attributed to the increasing use of TDF since its FDA approval in 2001.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:1139-6121